Celgene Corporation (CELG) to Present New and Updated Data across a Range of Blood Diseases at EHA 2018

0
987

Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018

Celgene Corporation (CELG) today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association (EHA) annual meeting in Stockholm, Sweden, from June 14-17, 2018.

“We are proud to be sharing new and updated data around our innovative hematological therapies at EHA 2018, which further our understanding of blood cancers and other blood-related diseases and allow us to continue to have a major impact on the lives of patients,” said Nadim Ahmed, President, Hematology & Oncology Franchise. “The data presented at EHA underscore the important role of immunomodulatory drugs at various stages of multiple myeloma, as well as illustrate our ongoing work in developing innovative treatment options, such as our erythroid maturation agent and CAR T cell therapies, for patients with life threatening blood disorders and cancers.”

At EHA this year, data will be presented on Revlimid in both Newly Diagnosed Multiple Myeloma and as maintenance treatment, and Pomalyst combination regimens following Revlimid use, including new data from the Phase III OPTIMISMM trial in the relapsed/refractory setting. Results from the Phase III RELEVANCE study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma patients will be featured during the meeting’s Presidential Symposium. Data will also be presented on Celgene’s CAR T cell therapies, including updated findings on bb2121 in multiple myeloma and pivotal clinical data on JCAR017 in lymphoma. Additionally, 2-year safety and efficacy data on luspatercept, an investigational compound, in beta-thalassemia will be presented.

Selected abstracts include:

CAR T

Abstract #S138; Oral; Friday, June 15, 12.30 – 12.45, Room A8. bb2121 anti-BCMA CAR T cell therapy in patients with relapsed/refractory multiple myeloma: updated results from a multicenter Phase I study. (Raje)

Abstract #S800; Oral; Saturday, June 16, 11:45 – 12:00, Room A1. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in r/r aggressive NHL (Abramson)

Newly-diagnosed Multiple Myeloma

Abstract #PS1429; Poster Presentation; Saturday, June 16, 17:30 – 19:00. Cost comparison of treatment strategies following initiation with Rd versus VMP plus daratumumab in newly diagnosed patients ineligible for ASCT. (Jackson)

Abstract #PF570; Poster Presentation; Friday, June 15, 17:30 – 19:00. Development of a predictive model of multiple myeloma (MM) patient outcomes based on treatment (tx) sequencing using data from The Connect® MM Patient Registry. (Jagannath)

Relapsed/Refractory Multiple Myeloma

Abstract #S847; Oral; Saturday, June 16, 16:00 – 16:15, Room A1. OPTIMISMM: Phase III trial of pomalidomide, bortezomib, and low‐dose dexamethasone vs bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed or refractory multiple myeloma. (Richardson)

Abstract #PF567; Poster Presentation; Friday, June 15, 17:30 – 19:00. Safety and efficacy of pomalidomide plus low-dose dexamethasone immediately following lenalidomide-based treatment failure in patients with relapsed and/or refractory multiple myeloma. (Siegel)

Abstract #PS1292; Poster Presentation; Saturday, June 16, 17:30 – 19:00. Pomalidomide plus low-dose dexamethasone plus daratumumab in patients with relapsed and/or refractory multiple myeloma after lenalidomide-based treatment failure. (Siegel)

Abstract #PF576; Poster Presentation; Friday, June 15, 17:30 – 19:00. Safety outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with lenalidomide for ≤ 24 months vs > 24 months in a European post-approval safety study (EU Pass). (Semenzato)

Maintenance in Multiple Myeloma

Abstract #PF562; Poster Presentation; Friday, June 15, 17:30 – 19:00. Maintenance after lenalidomide, bortezomib, and dexamethasone induction and transplant in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: an enhanced medical record analysis. (Fonseca)

LEAVE A REPLY

Please enter your comment!
Please enter your name here